|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.
|
17057021 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Activation of JAK2 by chromosomal translocation or point mutation is a recurrent event in hematopoietic malignancies, including acute leukemias and myeloproliferative disorders.
|
17077140 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
JAK2V617F, a somatic gain-of-function mutation involving the JAK2 tyrosine kinase gene, occurs in nearly all patients with polycythemia vera (PV) but also in a variable proportion of patients with other myeloid disorders; mutational frequency is estimated at approximately 50% in both essential thrombocythemia (ET) and myelofibrosis (MF), up to 20% in certain subcategories of atypical myeloproliferative disorder (atypical MPD), less than 3% in de novo myelodysplastic syndrome (MDS) or acute myeloid leukemia, and 0% in chronic myeloid leukemia (CML).
|
17124067 |
2006 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The discovery of the JAK2V617F allele represents an important advance in our understanding of the molecular pathogenesis of myeloproliferative disorders, though many questions remain regarding the role of a single allele in three clinically distinct disorders, the mechanism of activation of JAK2V617F, and the pathogenesis of JAK2-negative myeloproliferative disorders.
|
17133099 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The JAK2(V617F) mutation is present in almost all patients with polycythemia vera (PV), large proportions of patients with essential thrombocythemia and idiopathic myelofibrosis, and less frequently in atypical myeloproliferative disorders (MPD).
|
17145859 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
These data suggest that erlotinib may be used for treatment of JAK2(V617F)-positive PV and other myeloproliferative disorders.
|
17178722 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Discovery of a constitutively activating point mutation of the Janus kinase 2 (JAK2) receptor-associated tyrosine kinase in patients with polycythemia vera (PV) and other BCR/ABL-negative myeloproliferative disorders prompted many groups around the world to examine diverse subsets of patients with myeloid diseases for the prevalence of the JAK2 V617F mutation and its clinical and pathological associations.
|
17194663 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
|
17230231 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.
|
17249502 |
2006 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
|
17263783 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here we analyzed JAK2(V617F) mutation in 137 Chinese patients with myeloproliferative disorders by allele-specific polymerase chain reaction (PCR).
|
17266061 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
|
17267906 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
13 of the 27 JAK2 V617F-positive subjects with SVT were previously known to have a myeloproliferative disease (MPD).
|
17307838 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.
|
17315023 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
|
17317861 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
|
17363731 |
2007 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
LHGDN |
We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.
|
17379742 |
2007 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.
|
17379742 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders.
|
17384217 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
An acquired mutation in Janus kinase 2 (JAK2), V617F, has recently been identified in human myeloproliferative disorders.
|
17384221 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
|
17389152 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
|
17440677 |
2008 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
|
17443220 |
2007 |
|
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
LHGDN |
JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
|
17460706 |
2007 |
|
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
LHGDN |
JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder.
|
17488346 |
2007 |